Jiangsu Hengrui Medicine (600276.CH) - Here’s when Hengrui May Recover
We analyzed the possible future development trajectory of Hengrui's performance. Due to its "DNA" and development mode, after recovering,...
270 Views
China Healthcare Weekly (Mar.11) - 2022 Government Work Report, Expensive Monkeys, Technology Patent
We listed the key points about healthcare industry in 2022 government work report. Companies should notice the skyrocketed experimental monkey...
210 Views
GEM Weekly (11 Mar 2022): Chinese Macro Data; Samsung Electronics, Swiggy, Naver, Yum China
The Global Emerging Markets weekly provides a summary of the key news and related developments impacting the largest countries and constituents of...
253 Views
China ADRs Delisting - SEC Sets the Clock Ticking and Sends China ADRs Tripping
On 8th Mar 2022, Securities Exchange Commission (SEC) added five China ADR names to its provisional list of issuers under the Holding Foreign...
692 Views
Russia-Ukraine War: The Impact on China Healthcare
We analyzed the potential impact of Russia-Ukraine war on China healthcare industry including the delay of clinical trial projects in Ukraine,...
291 Views